Other surface targets that have been considered in the context of AML and antibody‐mediated elimination of LSC include CD44, CD45, CD47, CD93, CD96, CD157, CD330f, and CLL‐1.8, 30, 31, 32, 33, 34, 38, 43, 68, 69, 70. The gene discussed is CD96; the disease is acute myeloid leukemia.